Popular Articles

Raptor Pharmaceuticals Doses First Patient In Phase 2b Clinical Trial Of DR Cysteamine For Cystinosis
Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), announced that it has dosed the first patient in its Phase 2b clinical trial, conducted in collaboration with the University of California, San Diego ("UCSD"), to evaluate Raptor"s proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") capsules in nephropathic cystinosis ("cystinosis"), a rare genetic lysosomal storage disease. Under Raptor"s open Investigational New Drug application ("IND"), UCSD is performing the Raptor-sponsored trial at its General Clinical Research Center.
generic viagra online
UC Berkeley Researchers Bring Fluorescent Imaging To Mobile Phones For Low-cost Screening In The Field
Researchers at the University of California, Berkeley, are
News of the day
Shetland Seaweed For Safer Hair Dyes And Cosmetics
Scientists have launched a project to make hair dye out of seaweed from around the Shetland Islands.
Oncology

Accouncing The Leading European Congress On Cardiac Arrhythmias And Pacing: EUROPACE 2009

EUROPACE, the official congress of the European Heart Rhythm Association (EHRA), is the foremost European meeting on cardiac arrhythmias and pacing. More than 4,000 participants are expected to attend this year"s event, whose main themes are atrial fibrillation and sudden cardiac death. EHRA is a registered branch of the European Society of Cardiology (ESC). Its mission is to reduce the impact of cardiac arrhythmias and sudden cardiac death (SCD). EUROPACE 2009 will be held from 21-24 June in ICC Berlin, Germany. The press conference in Berlin will highlight several themes from the EUROPACE 2009 scientific programme: * How to improve the quality of care with a more uniform treatment of arrhythmias and better prevention of sudden cardiac death in all European countries. * Cardiac arrhythmias in athletes will be another important topic. A scientific session will consider the requirement for screening of all athletes to avoid sudden cardiac death and the implications of an abnormal electrocardiogram (ECG) in an athlete. The prevalence of cardiac arrhythmias in the athlete"s heart will be debated. * Hot Line sessions will be a major feature at EUROPACE 2009 (Tuesday 23 June). Devoted to late-breaking news from clinical trials, the ESC"s Hot Line sessions are renowned for making strong stories in medical news and will be discussed at the press conference. Also presented at the press conference: * Remote monitoring * Latest facts and figures on arrhythmias in Europe * Driving with ICD * Beat-It! Campaign Notes: 1. Sudden cardiac death claims more lives than stroke, lung cancer, breast cancer and AIDS combined. Incidence is less than 1% per year in the general population, but rising to more than 30% in high-risk post-MI subgroups. 2. Cardiac arrhythmia describes conditions in which heart beat is too fast, too slow, or irregular. The cause is abnormal electrical activity in the heart. Some arrhythmias may be life-threatening and result in sudden cardiac death. The average healthy heart beats 200,000 times per day. 3. The most common arrhythmia (after a skipped beat) is atrial fibrillation, which affects up to 5 per cent of all adults, mainly the over-65s. * Information on the scientific programme for Europace 2009 is available at http://spo.escardio.org/Welcome.aspx?eevtid=32 ESC Press Office European Society of Cardiology


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):